Avicanna Reports Q3 2023 Results
Acquisition of Medical Cannabis by Shoppers assets leading to the launch of MyMedi.ca. Record revenue of $6.27M, representing an increase of 90% over Q2, and 713% year-over-year. Improvements in perfo...
- Supported exchanges /
- TO /
- AVCN.TO
Avicanna Inc (AVCN TO) stock market data APIs
C$0.65
0.32(95.5%)
as of October 21, 2024
Price chart is built with Anychart
Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for consumer, medical, and pharmaceutical markets worldwide. It commercializes approximately thirty proprietary evidence-based finished products. The company provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios of cannabinoids under the RHO Phyto brand; and indication-specific pharmaceutical products to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders, such as Trunerox, an adjuvant treatment for seizures associated with Lennox-Gastaut Syndrome and Dravet Syndrome. It also offers active pharmaceutical ingredients comprising various cannabidiol, tetrahydrocannabinol, and cannabigerol for use in the development and production of food, cosmetics, medical, and pharmaceutical products under the Aureus Santa Marta brand. In addition, the company operates MyMedi.ca, a medical cannabis care platform that offers a diverse portfolio of products and bilingual pharmacist-led patient support programs, specialty services to veterans, and educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens, as well as collaborates with public and private payers for adjudication and reimbursement. The company has a research and collaboration agreement with a multinational European based pharmaceutical company to assess its proprietary SEDDS technology in combination with Collaborator's various drug delivery and pharmaceutical formats. Avicanna Inc. was incorporated in 2016 and is headquartered in Toronto, Canada.
Avicanna Inc Financial Data Overview
| 0.185 | |
| 0.65 | |
| - | |
| 0.575 | |
| -0.125 | |
| 0.2-0.6 | |
| 35 814 K | |
| 107 M | |
| 24 875 K | |
| -0.0188 | |
| 1.309 |
Our easy-to-use no-coding solutions help you get the data effortlessly:
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
General: {
Code:
'AVCN',
Type:
'Common Stock',
Name:
'Avicanna Inc',
Exchange:
'TO',
CurrencyCode:
'CAD',
CurrencyName:
'Canadian Dollar',
CurrencySymbol:
'C$',
CountryName:
'Canada',
CountryISO:
'CA',
OpenFigi:
NULL,
ISIN:
'CA05368K1003',
CIK:
NULL,
EmployerIdNumber:
NULL,
FiscalYearEnd:
'December',
IPODate:
NULL,
InternationalDomestic:
NULL,
Sector:
'Healthcare',
Industry:
'Drug Manufacturers - Specialty & Generic',
}
Avicanna Inc Fundamental Data is available in our Financial Data APIs
- Net Revenue 24 875 K
- EBITDA -6 307 489
- Earnings Per Share -0.1
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Avicanna Inc Earnings via APIs
- Latest Release 2024-08-14
- EPS/Forecast NaN
Get Avicanna Inc End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Get Avicanna Inc latest news via APIs
Avicanna Announces Appointment of Paul Fornazzari to Board of Directors
TORONTO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the commercialization of prop...
- AVICANNA INC
- DIRECTORS AND OFFICERS
- TORONTO STOCK EXCHANGE:AVCN
Do you have any questions?
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
